Natera, Inc. (NASDAQ:NTRA) Stock Holdings Lessened by Calamos Advisors LLC

Calamos Advisors LLC cut its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 99.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,970 shares of the medical research company’s stock after selling 10,003,975 shares during the quarter. Calamos Advisors LLC’s holdings in Natera were worth $3,636,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of NTRA. Covestor Ltd lifted its holdings in shares of Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 95 shares during the last quarter. Blue Trust Inc. boosted its holdings in shares of Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after buying an additional 97 shares during the period. GAMMA Investing LLC increased its position in shares of Natera by 32.7% in the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock worth $55,000 after acquiring an additional 106 shares in the last quarter. Hanseatic Management Services Inc. increased its position in shares of Natera by 12.0% in the fourth quarter. Hanseatic Management Services Inc. now owns 998 shares of the medical research company’s stock worth $158,000 after acquiring an additional 107 shares in the last quarter. Finally, Salem Investment Counselors Inc. raised its holdings in shares of Natera by 0.7% during the fourth quarter. Salem Investment Counselors Inc. now owns 16,280 shares of the medical research company’s stock valued at $2,577,000 after acquiring an additional 110 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Steven Leonard Chapman sold 4,728 shares of the business’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $146.41, for a total transaction of $692,226.48. Following the completion of the transaction, the chief executive officer now owns 185,034 shares of the company’s stock, valued at approximately $27,090,827.94. The trade was a 2.49 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Michael Burkes Brophy sold 43,502 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $176.88, for a total value of $7,694,633.76. Following the completion of the sale, the chief financial officer now directly owns 70,629 shares in the company, valued at $12,492,857.52. This trade represents a 38.12 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 311,731 shares of company stock worth $52,215,659. 7.60% of the stock is currently owned by insiders.

Natera Stock Performance

Shares of NTRA opened at $174.24 on Wednesday. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 12 month low of $66.68 and a 12 month high of $183.00. The company’s fifty day moving average is $167.26 and its 200-day moving average is $139.52. The firm has a market cap of $23.00 billion, a price-to-earnings ratio of -99.00 and a beta of 1.66.

Natera (NASDAQ:NTRA) last posted its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.31. The company had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business’s revenue was up 63.9% compared to the same quarter last year. During the same period last year, the company earned ($0.95) earnings per share. Equities analysts expect that Natera, Inc. will post -1.56 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on NTRA. Craig Hallum lifted their price objective on shares of Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. The Goldman Sachs Group lifted their price target on Natera from $160.00 to $190.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. Leerink Partners increased their price objective on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Sanford C. Bernstein lifted their target price on Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, January 10th. Finally, JPMorgan Chase & Co. increased their price target on shares of Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. One analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $165.88.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.